Ligand Pharmaceuticals reported $2.37 in EPS Earnings Per Share for its fiscal quarter ending in June of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2025 2.54 3.09 Nov/05
FY2026Q2 Jun/2026 2.37 1.95 1.60 Aug/06
FY2026Q1 Mar/2026 1.63 1.82 1.33 May/07
FY2025Q4 Dec/2025 2.02 1.49 1.27 Feb/26
FY2025Q3 Sep/2025 3.09 1.93 1.84 Nov/06




Eps Change Date
Agenus USD 1.02 1.32 Mar/2026
Amgen USD 6.29 1.14 Jun/2026
Anika Therapeutics USD 0.13 0.35 Dec/2025
Arrowhead Research USD -1.36 0.43 Jun/2026
Baxter International USD 0.56 0.2 Jun/2026
Bristol-Myers Squibb USD 2.04 0.46 Jun/2026
Eli Lilly USD 8.38 0.17 Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Enviri Corporation USD -1.02 0.92 Dec/2025
Gilead Sciences USD -6.75 8.78 Jun/2026
GlaxoSmithKline GBP 0.51 0.08 Jun/2026
Glaxosmithkline GBP 0.62 0.41 Mar/2026
Heron Therapeutics USD -0.02 0.02 Dec/2025
Insmed USD -0.06 0.7 Jun/2026
Intrexon USD -0.1 0.03 Jun/2024
Ionis Pharmaceuticals USD -0.69 0.13 Jun/2026
Karyopharm Therapeutics USD -1.02 1.2 Mar/2026
Ligand Pharmaceuticals USD 2.37 0.74 Jun/2026
MacroGenics USD -0.58 0.36 Mar/2026
Merck USD -0.13 1.15 Jun/2026
Pacira USD 0.73 0.13 Jun/2026
Pfizer USD 0.77 0.02 Jun/2026
Rigel Pharmaceuticals USD 0.7 0.76 Sep/2024
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Veracyte USD 0.54 0.02 Jun/2026